A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Trial Details

NCT ID
NCT05107674
Phase
PHASE1
Sponsor
Nurix Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • NX-1607
  • Paclitaxel
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Measurable disease per disease-specific response criteria.
  • Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatme…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →